Latest news with #CareConnect
Yahoo
01-04-2025
- Health
- Yahoo
Washington sues over RFK Jr.'s canceled health funding
Vaccination efforts are among the areas affected by the Trump administration's cuts to public health funding. (Photo by) Washington was among 23 states that sued the Trump administration Tuesday over the cancellation of $12 billion in federal funding to address infectious diseases, substance abuse and mental illness, including about $160 million for Washington. The lawsuit comes on the heels of the abrupt termination last week of grants related to disease tracking, vaccination efforts and other work that officials said could cost thousands of jobs in public health departments nationwide. This pot of money makes up $11 billion of the $12 billion cut. The cuts in Washington reportedly include $118 million for the Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases program, impacting 150 full-time employees. Losing this money will hurt the state's ability to respond to emerging outbreaks, including measles and bird flu, according to the complaint. That money also continued to support COVID-related surveillance efforts, the lawsuit says. In total, Washington's Department of Health stands to lose around $130 million, an agency spokesperson said last week, with the termination affecting upward of 200 department employees, and more at local health departments, tribal health clinics and community-based organizations. One of the specific programs affected is Care Connect, which the department launched early in the pandemic to provide food and other needs to people with COVID so they could isolate. The program later shifted to meet the needs of those suffering from long COVID, among other things. Washington Attorney General Nick Brown also cites the state's Care-A-Van mobile health clinics that provide vaccinations and other services to underserved communities. Officials have already had to cancel clinics due to the lost funding. The U.S. Department of Health and Human Services rolled back the grants 'for cause' because 'the pandemic is over,' so the funding is no longer needed, according to the lawsuit. The states counter that the money was never intended to only be used to respond to the COVID pandemic. The lawsuit also tackles the separate but simultaneous Trump administration axing of another $1 billion in Substance Abuse and Mental Health Services Administration funding, including $34 million for Washington. Brown is one of several attorneys general leading Tuesday's lawsuit, filed in U.S. District Court in Rhode Island. The Department of Health and Human Services and Secretary Robert F. Kennedy Jr. are named as defendants. The department didn't immediately respond to a request for comment Tuesday. 'We can't make America healthy by spreading preventable diseases,' Brown said. 'Aside from the illegality of these actions, the administration is also choosing to neglect the biggest public health challenges, including substance abuse and mental health crises, facing our communities.' The states say the cuts violate the Administrative Procedure Act by suddenly terminating the grants without much explanation. The plaintiffs asked a judge for a temporary restraining order to reverse the cuts. The state Department of Health's now-canceled federal grant dollars were expected to expire between June 2025 and July 2026, agency spokesperson Marisol Mata Somarribas said. Also on Tuesday, the Department of Health and Human Services began its purge of 10,000 federal workers. As part of the layoff announcement, Kennedy also said he'd be halving the number of Health and Human Services regional offices from 10 to five. Seattle's office serves Washington, Oregon, Idaho and Alaska. Its fate was unclear Tuesday. This is at least the 8th lawsuit Brown has led or joined against the Trump administration since January. Most have resulted in preliminary court orders blocking implementation of a variety of actions, including eliminating birthright citizenship, blocking gender-affirming care for minors and mass firings of federal workers.
Yahoo
27-03-2025
- Health
- Yahoo
$160M in WA health funding axed by Trump administration
(Photo by National Institutes of Health) Washington state is losing about $160 million in public health funding as part of the Trump administration's latest purge of federal grants. The money is part of $12 billion in cuts nationwide this week to funding for infectious disease tracking, mental health services and drug addiction treatment that could cost thousands of jobs in public health departments nationwide, according to news reports. Most of the money is congressionally approved COVID-era funding from the federal Centers for Disease Control and Prevention. In Washington state, the cuts will mean over $130 million in discontinued grants to the state Department of Health. The canceled money funds disease monitoring, reporting and work on vaccines for COVID-19 and other viruses, Department of Health spokesperson Marisol Mata Somarribas said. It also supports DOH computer systems related to these efforts. One of the programs impacted is Care Connect, which the department launched early in the pandemic to provide food and other needs to people with COVID so they could isolate. The program later shifted to meet long-term needs of those suffering from long COVID, among other things. The funding cut impacts work carried out by more than 200 full-time department employees, as well as staff at local health departments, tribal health clinics and community-based organizations, Mata Somarribas said. She added the department was still assessing the funding loss Thursday. The Trump administration terminated another $34 million in Substance Abuse and Mental Health Services Administration funding for the Washington State Health Care Authority, according to U.S. Sen. Patty Murray's office. Those dollars fund grants to local organizations working to provide mental health assistance and combat the opioid crisis. In a statement, Murray said the news 'could mean cuts to essential health services and layoffs of staff on the frontlines working to keep communities healthy, address public health threats and outbreaks, tackle the opioid epidemic and mental health crisis, and so much else.' This is the latest in the Trump administration's two-month siege of federal funding that has resulted in preliminary rebukes from judges telling the administration to reverse course. Meanwhile, on Thursday, the federal Department of Health and Human Services announced the layoff of 10,000 employees, including about 2,400 at the CDC. 'The reality is that, when we take funding away from public health systems, the systems just do not have the capacity, because they're chronically underfunded over the decades,' Dr. Umair Shah, Washington state's health secretary from late 2020 to January of this year, told The New York Times. In their operating budget proposal released this week, Washington state Senate Democrats included a reduction of 230 full-time employees in the Department of Health, which is currently budgeted for about 2,350 employees. Many of those are tied to the loss of federal COVID-era funding, said state Sen. June Robinson, D-Everett. 'It's a rough time,' Robinson said over the weekend. 'Public health always is funded in cycles of, you know, epidemics, and this is the downturn now.'
Yahoo
27-03-2025
- Health
- Yahoo
Feds cancel $12 billion of grants to state health department, including $130 million to Washington
Mar. 26—At least $130 million in federal funding to the Washington Department of Health was canceled this week. The cuts are part of at least $12 billion federal Health and Human Services grants to state health departments across the country, as first reported by NBC News. The terminated Washington DOH grants come from the Centers for Disease Control and Prevention, which is a branch of HHS. "This funding has been essential in supporting critical public health systems, including disease monitoring, reporting, and vaccine efforts for COVID-19 and other respiratory viruses," the Washington DOH said in a statement. The impacted grants include those for the following: * Epidemiology and Laboratory Capacity Program. * Immunizations. * Care Connect. * Partnership Evaluation. * Health Disparities. These cuts impact the work of more than 200 Washington DOH employees and will impact local health jurisdictions, the state department said. The Spokane Regional Health District did not immediately return a request for comment Wednesday on how their funding could be affected. The nationwide grant cuts include $11.4 billion from the Centers for Disease Control and Prevention and approximately $1 billion from the Substance Abuse and Mental Health Services Administration.
Mid East Info
28-01-2025
- Health
- Mid East Info
M42's Imperial College London Diabetes Centre doubles down on diabetes care with two new tech agreements - Middle East Business News and Information
Signing ceremonies take place at the M42 booth on day 2 of Arab Health Imperial College London Diabetes Centre will migrate to Medtronic's advanced Care Connect platform and adopt its innovative Galaxy platform It is also collaborating with innovative healthcare platform Karaz to streamline data integration. Dubai, United Arab Emirates, January, 2025: Imperial College London Diabetes Centre (ICLDC), part of the M42 group, is embracing the new technological advances in diabetes0 care by signing two innovative agreements, highlighting its commitment to patient empowerment and personalised and precision medicine. The signing ceremonies took place at the M42 booth on day 2 of Arab Health. The first agreement is with healthcare technology solutions provider Medtronic. ICLDC currently cares for over 1,000 patients in Abu Dhabi, that are on Medtronic's CareLink™ platform. Under the new agreement, it will migrate to Medtronic's advanced CareConnect and GALAXY platforms, which offer multiple additional features. CareConnect offers a user-friendly digital interface, designed as a more patient-centric alternative to the data-intensive CareLink™ dashboard. With customisable notifications, caregivers can stay promptly informed of critical events, such as abnormal glucose levels or device malfunctions. As an integrated remote patient monitoring system, CareConnect streamlines the patient care pathway by enhancing follow-up care and reducing the need for in-person clinical visits. By leveraging clinical insights alongside patient data, the platform prioritises cases based on urgency, ensuring timely interventions when additional care is needed. Physicians can manage patients remotely through a tailored communications channel, while patients benefit from access to consistent care and comprehensive remote monitoring. The platform also empowers care partners by enabling real-time data sharing and sending alerts directly to mobile devices. This fosters greater engagement from family members and caregivers, reducing response times to device alerts and facilitating quicker action. These features are especially crucial for managing time-sensitive conditions like diabetes. As part of the agreement, ICLDC will also adopt Medtronic's innovative GALAXY platform. GALAXY provides tailored reporting and insights, enabling clinicians to focus on specific patient needs and broader operational goals. It allows clinicians, researchers and the organisation to see aggregated patient data, providing a comprehensive view of patient health and facilitating strategic improvements in outcomes. Clinicians can review data specific to individual patients, including real-time insights and historical trends, to optimise personalised care. Robust statistical capabilities allow for trend identification, clinical outcome benchmarking, and actionable insights derived from real-world evidence. By transitioning to GALAXY, ICLDC enhances its ability to monitor patients' clinical and diagnostic data while empowering its vision to alleviate the burden of diabetes. To address the challenges of managing diverse technological solutions, ICLDC is also collaborating with innovative healthcare platform, Karaz, to streamline data integration. Currently, caregivers often need to check multiple software platforms to access data from various insulin and continuous glucose monitoring (CGM) devices. The Karaz platform will consolidate patient data into a single dashboard, simplifying caregivers' workflow and improving efficiency. By emphasizing predictive modeling and data interpretation to identify trends and anticipate patient needs, its intuitive interface empowers patients to actively participate in their health management. The platform integrates predictive insights from Karaz with Galaxy's clinical analytics, enabling healthcare providers to gain a more comprehensive understanding of patient health. Dr. Mai Al Jaber, CEO, Outpatient Care at M42, said: 'Today marks a transformative milestone in our relentless pursuit to revolutionise diabetes care. Imperial College London Diabetes Centre's partnership with Medtronic reinforces our battle against diabetes by empowering patients. It also empowers our caregivers to look at the bigger picture, identify patients with certain risk factors, and apply therapies aligned with published guidelines in a risk-stratified manner. Through the use of Medtronic's advanced CareConnect and Galaxy platforms, combined with our partnership with Karaz, we're establishing a new benchmark for proactive, personalised patient care. We're not merely adopting technology; we're leading its integration to give individuals with diabetes more control, effortless health management, and better health outcomes. This marks a crucial milestone in reshaping diabetes care, both locally and globally.' About Imperial College London Diabetes Centre: Imperial College London Diabetes Centre (ICLDC), an M42 company, is a state-of-the-art outpatient facility that specialises in diabetes treatment, research, training, and public health awareness. In just over a decade, the Centre has gained international renown for its holistic approach to the treatment of diabetes and related complications that enables patients to receive the full spectrum of care they need in one place. With more than 80 diabetes professionals and endocrinologists under one roof, Imperial College London Diabetes Centre offers best-in-class medical attention from first diagnosis to disease management across 11 specialist practice areas including adult and paediatric endocrinology, treatment of metabolic and electrolyte disorders, pre- and post-bariatric surgery care, heart disease prevention, nutritional advice, diabetes education services, ophthalmology, nephrology, and podiatry. ICLDC was established in 2006 in Abu Dhabi by Mubadala in partnership with the UK's Imperial College London to address the growing demand for diabetes care in the UAE. The centre now operates three branches across Abu Dhabi and Al Ain, touching the lives of more than one million people through patient-centric programmes and public health initiatives. In 2007, ICLDC launched Diabetes. Knowledge. Action, now the longest running public health awareness campaign in the country. The initiative promotes an active lifestyle through an ongoing calendar of events for the whole community – Major activations include an annual walkathon that coincides with the World Diabetes Day in November. ICLDC holds the Joint Commission International (JCI) Clinical Care Program Certification in Outpatient Diabetes Management and JCI Accreditation for Ambulatory Care. About M42: M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally. Established in 2022, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.
Hi Dubai
28-01-2025
- Health
- Hi Dubai
ICLDC Enhances Diabetes Care with New Partnerships at Arab Health
The Imperial College London Diabetes Centre (ICLDC), part of the M42 group, has signed two significant agreements at Arab Health in Dubai, underscoring its commitment to advancing diabetes care through patient empowerment and precision medicine. ICLDC's first agreement, in collaboration with Medtronic, aims to enhance its diabetes care services for over 1,000 patients in Abu Dhabi. The centre, which currently utilizes Medtronic's CareLink™ platform, will transition to Medtronic's advanced CareConnect and GALAXY platforms. CareConnect, designed to be more patient-centric, offers a streamlined interface and customizable notifications for critical events, enabling caregivers to monitor patients remotely. The platform integrates remote patient monitoring, ensuring timely interventions and reducing in-person visits. In addition, the GALAXY platform will provide tailored reporting, offering clinicians and researchers comprehensive patient insights, improving both individual care and operational strategies. ICLDC is also collaborating with Karaz, an innovative healthcare platform, to simplify data integration. The Karaz platform will consolidate patient information from various devices into a single, user-friendly dashboard, enhancing efficiency for caregivers. Dr. Mai Al Jaber, CEO of Outpatient Care at M42, remarked, "This partnership marks a transformative step in diabetes care, enabling us to offer proactive, personalized treatments and better outcomes. Through CareConnect, GALAXY, and Karaz, we are leading the integration of advanced technologies to revolutionize diabetes management locally and globally." These agreements represent ICLDC's ongoing efforts to reshape diabetes care, making it more accessible, efficient, and focused on individual patient needs. News Source: Emirates News Agency
